The goal is to attract a licensing partner after completing phase I/II in order to continue the development. An alternative scenario is to find a partner before entering clinical studies, based on a precise development plan

It is a very exciting result for any drug candidate to trigger a protein like Pentraxin-3 with such a broad spectrum of effects

Aptahem is currently focusing on sepsis, but there is possibility for potentially expanding the indication. At present, no such decision has been made, but we are not ruling it out